Use of a clinician-facing dashboard combined with a best practice alert helped increase rates of HLA-B*58:01 genetic testing among patients prescribed allopurinol.

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial We previously identified 12 single nucleotide polymorphisms within the HLA region as ...

A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy. About ...

STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, ...

Please provide your email address to receive an email when new articles are posted on . An analysis of registry data from the United Network for Organ Sharing suggests that human leukocyte antigen ...

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ...

Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...

This case study describes an atypically severe attack of uveitis in a patient with HLA-B27-positive ankylosing spondylitis. Although TNF-inhibitor therapy was extremely effective regarding articular ...